SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). 26. Dezember 2018 Retz, M., Bedke, J., Bögemann, M., Grimm, M.-O., Zimmermann, U., Müller, L., Leiber, C., Teber, D., Wirth, M., Bolenz, C., van Alphen, R., De Santis, M., Beeker, A., Lehmann, J., Indorf, M., Frank, M., Bokemeyer, C., Gschwend, J.E., 2019. Eur J Canc 107, 37–45. doi:10.1016/j.ejca.2018.11.001 Abstract Prophylaxis of Chemotherapy-Induced Neutropenia and Febrile Neutropenia with Lipegfilgrastim in 2489 Cancer Patients: Final Results from the Non-Interventional Study NADIR Fietz, T., Lück, A., Schulz, H., Harde, J., Losem, C., Grebhardt, S., Wolff, T., Potthoff, K., Müller, U., Zaiss, M., Kurbacher, C.M. Current Medical Research… Weiterlesen Final results from IMPROVE: A randomized, controlled, open-label, cross-over phase IV study to determine the patients’ preference for either combined endocrine therapy (exemestane plus everolimus) or immunochemotherapy (capecitabine plus bevacizumab) as first line treatment for advanced HR+/HER2- breast cancer. Kurbacher, C., Söling, U., Hahn, A., Chiabudini, M., Maintz, C., Rieger, L., Falkenstein, J., Runkel, E., Potthoff, K., Decker, T., 2019. Cancer Res 79 (4… Weiterlesen